

FOI 3667

1st April 2026

FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST

How many early-stage (non-metastatic or Stages 1-3) non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:

- **Atezolizumab (Tecentriq)**
- **Durvalumab (Imfinzi)**
- **Nivolumab (Opdivo)**
- **Pembrolizumab (Keytruda)**
- **Chemotherapy**
- **Radiotherapy**
- **Chemotherapy AND Radiotherapy**
- **Osimertinib**

Response:

This information is not recorded centrally and therefore retrieving it would involve a manual search of patient records. As such we cannot provide this as the cost of locating and retrieving the information exceeds the “appropriate limit” as stated in the Freedom of Information (Fees and Appropriate Limit) Regulations 2004. In order to obtain this information from a number of individual patient records would exceed the £450 limit and is therefore cost prohibitive.

Under section 12 of the Freedom of Information Act 2000, Public Authorities are not obliged to comply with an information request where to do so would exceed the cost limit

In addition, it would not be appropriate to search through individual patient records for the purposes for responding to a FOI request, there would be no patient expectation that medical records would be used in this way.

Furthermore, under Section 16 of the Freedom of Information Act, we can advise that it would require an extensive manual review of records just to ascertain if information relevant to your request is held. As such, we advise that there is no way to refine this request to bring it within the appropriate limit.

How many patients has your trust treated in the last 3 months with Pembrolizumab for stage II Melanoma?

Response:

None

Email: Foi.Team@Southerntrust.hscni.net